A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-Mcg Dose

This study has been completed.

Study NCT00001056 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

First Received: November 2, 1999 Last Updated: June 23, 2005 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given